Nanoparticle for DSA Removal

Kidney Failure Clinical Trial

Official title: Donor-specific Anti-human Leukocyte Antigen Antibodies (DSA) Re-moval From Patient Blood Using Functionalized Nanoparticles - an ex Vivo Feasibility and Proof of Principle Study

Status Recruiting

Clinical Trial Summary

Magnetic nanoparticles, coated with human leukocyte antigens (HLA) to capture anti-HLA antibodies with donor specificity (donor-specific antibodies, DSA), will be tested ex-vivo.

Clinical Trial Description

This project aims at developing a new method using human leukocyte antigens (HLA)-coated magnetic nanoparticles to remove donor-specific antibodies (DSA) from the patients' blood ex vivo, while trying to keep the blood unaffected after exposure to the particles.

Nanoparticles will be engineered and tested ex vivo. While nanoparticles were successfully coated with macromolecules such as antibodies in the past, this is a new approach, which will be performed by the research group.

The goal of this project is to capture DSA in patient blood ex vivo and to remove them by magnetic separation. Efficacy and safety of this procedure will be assessed, especially the interaction of these novel particles with other blood components such as coagulation factors or effector cells, which could produce inflammatory mediators. According analyses are initiated and carried out. ;

Related Conditions & MeSH terms

• Kidney Failure
• Presence of Donor Specific Antibodies
• Renal Insufficiency

• NCT number: NCT04277377
• Study type: Observational
• Source: University of Zurich
• Contact: Beatrice Beck Schimmer, Prof
• Phone: +41442552696
• Email: beatrice.beck@usz.ch
• Status: Recruiting
• Start date: October 5, 2021
• Completion date: February 28, 2026